Studies Currently Seeking Volunteers

Study NameInvestigatorCategoryStudy Added
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19 Clint Wilson, M.D. COVID8/13/2020
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 Clint Wilson, M.D. COVID7/7/2020
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer Destin Black, M.D. Cancer4/21/2020
A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (3000-03-005/ENGOT-OV44) Destin Black, M.D. Cancer4/21/2020
A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis   Diabetes, Gastrointestinal4/21/2020
A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis   Diabetes, Gastrointestinal4/21/2020
12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis   Diabetes, Gastrointestinal4/21/2020
EVALUATION OF PATIENT OUTCOMES FROM THE KIDNEY ALLOGRAFT OUTCOMES ALLOSURE REGISTRY (KOAR) Neeraj Singh, M.D. Kidney4/21/2020
D5290C00004-A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)   Pediatric4/21/2020
An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas Anil Veluvolu, M.D. Cancer4/21/2020
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)   Cancer4/21/2020
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma   Cancer4/21/2020
Malleable Treatment – the Tactra Erectile Restoration Study Gerard Henry, M.D. Urology4/21/2020
Advances in Biofilm and the Future of Infection Prevention in Prosthetic Urology Gerard Henry, M.D. Urology4/21/2020
Artificial Urinary Sphincter Clinical Outcomes Gerard Henry, M.D. Urology4/21/2020
Post Approval Study of the AcrySof® IQ ReSTOR® Toric IntraOcular Lens Dr. Wyche Coleman, M.D. 4/21/2020
A Post-Market Study Evaluating the Safety of Infinity DBS System with MR Conditional Labeling Dr. Jessica Wilden, M.D. Radiology4/21/2020
A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy.   Cancer, Radiation Therapy4/21/2020
An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas   Cancer4/21/2020
informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia   Cancer4/21/2020
A Pivotal, Double-blind, Randomized, Placebo-controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck   Cancer, Radiation Therapy4/21/2020
Phase 3 Randomized Trial Comparing Overall Survival After Photon versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB Non-Small Cell Lung Cancer (NSCLC)   Cancer4/21/2020
Prospective Research Assessments in Multiple Myeloma: An Observational Evaluation (PREAMBLE)   Cancer4/21/2020
A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE)   Cancer, Radiation Therapy4/21/2020
Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy   Cancer, Radiation Therapy4/21/2020
Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)   Cancer, Radiation Therapy4/21/2020
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 & 6 Inhibitor, in Combination with Fulvestrant Compared to Chemotherapy in Women with HR Positive, HER2 Negative Metastatic Breast Cancer with Visceral Metastases   Breast Cancer, Cancer4/21/2020
Phase 2 Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer   Cancer4/21/2020
The COVID-19 and Cancer Consortium (CCC19) Registry   Cancer, COVID4/21/2020
Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19 Joseph Bocchini, M.D. COVID4/9/2020
FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor a-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Destin Black, M.D. Cancer2/13/2018
Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy Destin Black, M.D. Cancer2/13/2018
Pragmatic Phase III Randomized Trial of Proton versus Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial   Breast Cancer, Cancer, Radiation Therapy2/17/2017
Observational Study of Patients with Polycythemia Vera in U.S. Clinical Practices (REVEAL)   Cancer11/12/2015